Regulus HCV Candidate Is Out, But New CEO Has BD Pedigree
Executive Summary
The micro-RNA-focused biotech believes the jaundice seen with HCV candidate RG-101 was specific to the drug, not the target or delivery system, but is switching focus to other promising programs, such RG-012 for Alport syndrome.
You may also be interested in...
Finance Watch: Regulus Shrinks To Preserve Cash, Ironwood Cuts Jobs Ahead Of Split
Public Company Edition: Long-struggling Regulus is laying off employees and pausing its two clinical programs. Also, Ironwood is shuffling staff ahead of splitting into two companies and will cut 40 jobs in the process. And among several loan agreements and note sales, Tesaro borrows another $200m.
With Dicerna's NASH Asset, Boehringer Found What It Was Looking For
In eyeing NASH, the firms both zeroed in on the same target, considered inaccessible to traditional modalities. The deal gives BI an RNAi approach, joining its Phase II anti-inflammatory candidate for NASH.
Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace
Kala follows July's first biopharma IPO from Ionis spinout Akcea into the stock market. Amicus, Arena and othera go high with major offerings, while Inovio and Regulus go low. Also, Galena, Neothetics provide updates on their hunts for "strategic alternatives."